Sanofi India Share Price Rise 6% After Q4 Results and Dividend Announcement

Sanofi India share price surged up to 6% on Friday after the company announced strong Q4 results and a final dividend of ₹117 per share. However, market corrections later led to some profit booking.

Sanofi India Share Price Movement

Sanofi India’s stock opened at ₹5001.40 on the BSE, slightly higher than the previous close of ₹4996.75. The stock climbed to an intraday high of ₹5317.75, marking a gain of over 6% in morning trade. However, as the broader market declined, with Sensex falling nearly 1000 points, the stock gave up most of its gains.

Sanofi India Q4 Results

For the October–December 2024 quarter (Q4), Sanofi India reported a 31% increase in profit from continuing operations at ₹91.3 crore, compared to ₹69.7 crore in the same period last year. The company follows a January–December financial year, making this its final quarter.

• Revenue from operations stood at ₹515 crore, up 10% from ₹469 crore in Q4 2023.
• Operating profit grew 21%, reaching ₹108 crore, compared to ₹90 crore in Q4 2023.

Key Growth Drivers

Sanofi India’s Diabetes care segment showed strong performance, with double-digit growth for Toujeo and a successful launch of Soliqua.
The company also highlighted its new partnerships in Central Nervous System (CNS) and Cardiovascular (CV) segments, which have helped expand its market reach.

Sanofi India Dividend Announcement

Sanofi India has declared a final dividend of ₹117 per share (face value ₹10 each) for the financial year ending December 31, 2024. The dividend is subject to shareholder approval.

Sanofi India’s strong financial performance and attractive dividend payout have reinforced investor confidence despite overall market volatility.

Conclusion

Sanofi India’s solid earnings and high dividend reinforced investor confidence, though broader market weakness led to partial profit booking.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.